Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cu-AKY-2519
- Development stage
- Unknown
- Lead developer
- Aktis Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Cu-AKY-2519 (also known as [64Cu]Cu-AKY-2519) is a clinical-stage miniprotein radioconjugate targeting B7-H3 (CD276), developed by Aktis Oncology. It is designed as a diagnostic imaging agent utilizing the positron-emitting radioisotope copper-64 (64Cu) for PET imaging and dosimetry, forming a theranostic pair with the therapeutic actinium-225-labeled counterpart, [225Ac]Ac-AKY-2519. The miniprotein scaffold of AKY-2519 is engineered for high tumor penetration, rapid internalization, and prolonged retention in B7-H3-expressing cancer cells, coupled with rapid renal clearance to minimize normal tissue exposure. Cu-AKY-2519 is currently being evaluated in Phase 1b clinical trials for the imaging and dosimetry of patients with B7-H3-expressing solid tumors, including metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC).
- Other names
- 64 Copper AKY 251964Cu-AKY-2519[64Cu]Cu-AKY-2519copper-64 AKY-2519copper64 AKY-2519copper 64 AKY-2519
02
Targets
B7-H3
Beyond the preview
Go deeper on Cu-AKY-2519.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cu-AKY-2519.